Activation of Agouti-related peptide (AgRP) neurons potently promotes feeding, and chronically altering their activity also affects peripheral glucose homeostasis. We demonstrate that acute activation of AgRP neurons causes insulin resistance through impairment of insulin-stimulated glucose uptake into brown adipose tissue (BAT). AgRP neuron activation acutely reprograms gene expression in BAT toward a myogenic signature, including increased expression of myostatin. Interference with myostatin activity improves insulin sensitivity that was impaired by AgRP neurons activation. Optogenetic circuitry mapping reveals that feeding and insulin sensitivity are controlled by both distinct and overlapping projections. Stimulation of AgRP / LHA projections impairs insulin sensitivity and promotes feeding while activation of AgRP / anterior bed nucleus of the stria terminalis (aBNST) vl projections, distinct from AgRP / aBNST dm projections controlling feeding, mediate the effect of AgRP neuron activation on BAT-myostatin expression and insulin sensitivity. Collectively, our results suggest that AgRP neurons in mice induce not only eating, but also insulin resistance by stimulating expression of muscle-related genes in BAT, revealing a mechanism by which these neurons rapidly coordinate hunger states with glucose homeostasis.
In Brief
Neural circuits containing AgRP neurons coordinate hunger states with glucose homeostasis by inducing, in addition to eating, insulin resistance via stimulating expression of muscle-related genes in brown adipose tissue that inhibit glucose uptake.
SUMMARY
Activation of Agouti-related peptide (AgRP) neurons potently promotes feeding, and chronically altering their activity also affects peripheral glucose homeostasis. We demonstrate that acute activation of AgRP neurons causes insulin resistance through impairment of insulin-stimulated glucose uptake into brown adipose tissue (BAT). AgRP neuron activation acutely reprograms gene expression in BAT toward a myogenic signature, including increased expression of myostatin. Interference with myostatin activity improves insulin sensitivity that was impaired by AgRP neurons activation. Optogenetic circuitry mapping reveals that feeding and insulin sensitivity are controlled by both distinct and overlapping projections. Stimulation of AgRP / LHA projections impairs insulin sensitivity and promotes feeding while activation of AgRP / anterior bed nucleus of the stria terminalis (aBNST) vl projections, distinct from AgRP / aBNST dm projections controlling feeding, mediate the effect of AgRP neuron activation on BAT-myostatin expression and insulin sensitivity. Collectively, our results suggest that AgRP neurons in mice induce not only eating, but also insulin resistance by stimulating expression of muscle-related genes in BAT, revealing a mechanism by which these neurons rapidly coordinate hunger states with glucose homeostasis.
INTRODUCTION
Obesity represents a major health burden, currently affecting more than 30% of Western populations and it results from a de-regulated balance between caloric intake and energy expenditure. Energy homeostasis is maintained through hormonal and nutrient feedback signals communicating peripheral fuel availability to the CNS to accordingly adapt behavioral and autonomic responses through the control of energy intake and expenditure . Here, acute regulation of AgRP neurons plays a predominant role in control of feeding, as inducible ablation of these neurons in adult mice leads to immediate cessation of feeding and as acute chemogenetic or optogenetic activation of these neurons provokes voracious feeding (Gropp et al., 2005; Luquet et al., 2005; Aponte et al., 2011; Krashes et al., 2011) . Of note, the food intake regulatory function of these neurons is not only mediated through AgRP release, but also by co-release of neuropeptide Y (NPY) and the inhibitory neurotransmitter GABA (Atasoy et al., 2012) . According to their fundamental function in control of feeding, AgRP neurons integrate numerous signals from the periphery, which communicate nutrient availability in the organism, including ghrelin, insulin, glucose, and the purine base derivative, UDP (Andrews et al., 2008; Plum et al., 2006; Kö nner et al., 2007; Parton et al., 2007; Steculorum et al., 2015) .
Recent sophisticated optogenetic neurocircuitry mapping experiments have provided important new insights into the neuronal network architecture underlying the control of feeding. Betley et al. (2013) demonstrated that redundant pathways originating from AgRP neurons and projecting to the anterior bed nucleus of the stria terminalis (aBNST), paraventricular hypothalamic nucleus (PVH), lateral hypothalamus (LHA), and paraventricular thalamic nucleus (PVT) mediate AgRP neuron-evoked (C and E) Pie charts represent the ratio between CNO-responsive and non-responsive neurons. (C) Action potential (AP) frequency of responding AgRP neurons (n total = 11: n responding = 7 and n non-responding = 4), and (E) of responding POMC neurons (n total = 19: n responding = 11 and n non-responding = 8).
(D and F) Example rate histograms and the respective original recordings of an AgRP neuron and a POMC neuron, respectively. Numbered arrows mark bins of which original traces in the lower panel are extracted.
(legend continued on next page) stimulation of feeding. Very recently, another characteristic of the homeostatic regulation of feeding governed by AgRP neurons was discovered, where AgRP neurons exhibit properties consistent with a negative-valence teaching signal (Betley et al., 2015) .
In addition to their crucial role in controlling feeding, AgRP neurons and the melanocortin circuitry have been implicated in the long-term regulation of peripheral glucose homeostasis (Kö nner et al., 2007) . From an evolutionary point of view, it is reasonable to assume that the same neurons, which control uptake of nutrients from outside the body according to energy state, also control nutrient fluxes across different peripheral organs (Vogt and Brü ning, 2013) . Along this line, we demonstrated that insulin's ability to inhibit AgRP neuron firing is required for its effect to suppress hepatic glucose production in mice (Kö nner et al., 2007) . Similarly, chronic simultaneous ablation of insulin and leptin receptors from pro-opiomelanocortin (POMC) neurons results in profound deregulation of peripheral glucose metabolism (Hill et al., 2010) . In addition, targeted re-expression of the MC4R revealed distinct effector sites for MC4R-dependent control of feeding and chronic regulation of peripheral glucose metabolism (Morgan et al., 2015; Berglund et al., 2014; Balthasar et al., 2005) . These studies were, however, all based on models with chronic alterations of signaling systems in AgRP and POMC neurons. Accordingly, it remained undefined whether acute activation of AgRP and POMC neurons exerts acute glucose and insulin sensitivity regulatory effects and if so, which mechanism(s) are involved in this regulation both within the CNS as well as in peripheral organs. Exactly defining the food intake and glucose regulatory functions of these neurons is of critical importance, since obesity-associated hypothalamic inflammation and associated alterations of AgRP neuron activity can contribute to the manifestation of obesity and progression of insulin resistance (Tsaousidou et al., 2014; Kleinridders et al., 2009; . Moreover, improved glucose metabolism in high fat diet (HFD)-fed mice upon toxin-mediated ablation of AgRPneurons further highlights the dependence of metabolic alterations in obesity on the activity of these cells (Joly-Amado et al., 2012) .
Therefore, we employed chemogenetic and optogenetic tools to investigate if and how activation of AgRP or POMC neurons affects the short-term regulation of systemic glucose homeostasis. We find that activation of AgRP neurons, but not of POMC neurons, acutely impairs systemic insulin sensitivity. Acute activation of AgRP neurons inhibits insulin-stimulated glucose uptake in BAT, regulates sympathetic nerve activity to BAT, and leads to altered gene expression in BAT with upregulation of a myogenic gene signature, including myostatin. Myostatin-neutralizing antibodies attenuated the insulin resistance-inducing effect of AgRP neuron activation. Employing optogenetic circuitry mapping approaches, we delineate the distinct and overlapping architecture of the neurocircuitry responsible for acute feeding and insulin sensitivity.
RESULTS

Chemogenetic Activation of AgRP Neurons Causes Insulin Resistance
To investigate the effect of activating AgRP neurons on systemic glucose homeostasis and insulin sensitivity, we generated mice that allow for Cre-dependent expression of the stimulatory DREADD-receptors hM3D Gq from the ROSA26-locus (Alexander et al., 2009) (Figure S1A Figures 1C and 1D ). POMC neurons also elicited action potential firing upon CNO-induced activation of these neurons in hM3D Gq POMC mice (Figures 1E and 1F) . However, at the same dose of CNO (0.3 mM), only 20% of POMC neurons responded with a significant increase in action potential frequency ( Figure S1B ). When we increased the dose of CNO to 3 mM, 60% of POMC neurons responded to CNO incubation including some that had not responded to previous application of 0.3 mM CNO ( Figures 1E, 1F , and S1B).
In (n = 4 versus 4), and (H) fasted mice (n = 7-8 in each group) and random fed mice (n = 8). Scale bars, 100 mm. 3V, third ventricle. Data are represented as boxplots and generated according to the ''Tukey method'' (mean, +; median, horizontal line) (C and E) and as mean ± SEM (G-I). *p % 0.05, **p % 0.01, and ***p % 0.001 as determined by paired Student's t test (C and E) and unpaired Student's t test (G-I). See also Figure S1B .
has been published previously ( Figure S1E ) (Aponte et al., 2011; Krashes et al., 2011) . Similarly, AgRP neuron activation in hM3D Gq AgRP mice increased locomotor activity 140 min following CNO injection in the absence of food ( Figure S1F ) consistent with previous reports (Dietrich et al., 2015; Krashes et al., 2011) . Moreover, activation of POMC neurons upon CNO injection of hM3D Gq POMC mice during the dark phase resulted in acute suppression of feeding ( Figure S1G ). While previous studies reported that only prolonged activation of POMC neurons suppresses feeding (Aponte et al., 2011; Zhan et al., 2013) , CNO administration in hM3D Gq POMC mice significantly decreases feeding after 1 hr. This discrepancy can originate from different methodical aspects such as number of neurons activated by the respective approaches. Nevertheless, hM3D Gqdependent chemogenetic activation represents a suitable approach to study the effects of acute activation of AgRP and POMC neurons in vivo. Next, we investigated the effect of acutely activating AgRP or POMC neurons on peripheral glucose homeostasis and insulin sensitivity by assessing glucose and insulin tolerance after CNO injection to hM3D Gq AgRP and hM3D Gq POMC mice and their littermate controls (Figures S2A and S2B) . To avoid any confounding effect of altered food intake, all experiments were performed without providing food to the animals subsequent to 
CNO injection. We found that injection of CNO in hM3D Gq
AgRP mice acutely impaired glucose tolerance and insulin tolerance (Figures 2A and 2B ). In contrast, activating POMC neurons in hM3D Gq POMC mice had no effect on either glucose tolerance or insulin sensitivity (Figures 2C and  2D) , not even when they were injected with 3 mg/kg BW of CNO or upon prolonged application of CNO 16 hr prior to the GTT ( Figures S2C-S2E ). We further employed a complimentary approach by optogenetically activating AgRP neurons (Figures S2F and S2G) . Therefore, we crossed mice allowing for Cre-dependent expression of channelrhodopsin 2 (ChR2) (Madisen et al., 2012) with AgRPCre mice to yield ChR2
AgRP animals and AgRP Cre -negative control littermates (ChR2 WT ) ( Figure S2H ). Unilateral optogenetic activation of AgRP neurons in the ARH of these mice resulted in pronounced induction of feeding as previously reported (Aponte et al., 2011) ( Figure S2I ). Moreover, optogenetic activation of AgRP neurons in ChR2 AgRP mice induced severe insulin resistance, without affecting glucose tolerance (Figures 2E and 2F) .
Activation of AgRP Neurons Impairs Insulin-Stimulated
Glucose Uptake in BAT To define which aspect of peripheral glucose homeostasis is modulated upon acute activation of AgRP neurons, we performed euglycemic-hyperinsulinemic clamps in hM3D Gq AgRP and control mice ( Figure S3A ). To circumvent any potentially confounding effect of altered locomotor activity following AgRP neuron activation, the clamp studies were performed in restrained animals. While both groups of mice achieved the same degree of glycemia during the steady-state phase of the clamp ( Figure S3B ), the glucose infusion rate (GIR) required to maintain euglycemia was significantly reduced in hM3D Gq AgRP mice ( Figure 3A ).
When we assessed hepatic glucose production (HGP), hM3D Gq AgRP and control mice exhibited no significant differences in baseline or in insulin-suppressed rate of HGP (Figure 3B) . In contrast, insulin's ability to promote glucose uptake into brown adipose tissue (BAT) was significantly reduced by 50% upon AgRP neuron activation, while it remained unaltered in white adipose tissue (WAT) and skeletal muscle ( Figure 3C ). Additionally, under non-clamp conditions, acute activation of AgRP neurons increased serum insulin concentrations 1 hr after CNO injection, but did not significantly modulate glucagon or corticosterone levels ( Figure 3D ). Thus, acutely activating AgRP neurons primarily impairs systemic insulin sensitivity via inhibition of insulin-stimulated glucose uptake in BAT. Consistent with this finding, insulin-stimulated BAT glucose uptake is also reduced in obese, HFD-fed mice, in which AgRP neuron activity is chronically altered ) ( Figures  S3G-S3I ). In contrast to hM3D Gq AgRP mice, CNO treatment of hM3D Gq POMC mice had no effect on GIR, tissue-specific glucose uptake rates or insulin's ability to suppress HGP during euglycemic-hyperinsulinemic clamps ( Figures S3C-S3F ). Thus, acute activation of AgRP neurons, but not POMC neurons, affects systemic glucose metabolism and insulin sensitivity.
Activation of AgRP Neurons Promotes a Myogenic Gene Expression Profile in BAT
Since acute activation of AgRP neurons lead to inhibition of BAT glucose uptake, we asked whether this effect was accom- panied by acute changes in gene expression, which could point to the mechanism(s) underlying the development of insulin resistance. We therefore performed a gene expression analysis on BAT-RNA of control and ChR2 AgRP mice that had been photo-stimulated in the ARH (ChR2 ARH AgRP ) for 1 hr. This analysis revealed 192 significantly differentially regulated genes (±1.5-fold; p < 0.005) in BAT of these mice ( Figure 4A ; Table S1 ). Interestingly, gene ontology enrichment analysis revealed an overrepresentation of genes associated with myocyte differentiation and muscle function ( Figure 4B ; Table S2 ). In fact, out of 162 upregulated genes, 33 where annotated as muscle-associated transcripts. Interestingly, one of the strongest upregulated genes was myostatin (Mstn), which expression was increased by 18-fold upon somatic photostimulation of AgRP neurons (Table S1 ).
To further validate the increased myostatin mRNA expression in BAT after optogenetic activation of AgRP neurons, we assessed its mRNA expression and that of other muscle-associated candidate genes identified in the microarray analysis in BAT of control and hM3D Gq AgRP mice 1 hr following CNO application. This analysis confirmed profound AgRP neuron activation-dependent transcriptional upregulation of myostatin and ankyrin repeat and SOCS box-containing 15 (Asb15) ( Figure 4C ). Moreover, consistent with the effect of AgRP neuron activation to only inhibit glucose uptake in BAT, myostatin mRNA expression was found to be increased in BAT following chemogenetic activation of AgRP neurons, but not in skeletal muscle or white adipose tissue depots ( Figure S4A ). To further investigate whether the effect of optogenetic or chemogenetic activation of AgRP-neurons on BAT myostatin mRNA expression reflected a physiological, feeding state-dependent regulation, we next compared myostatin expression in BAT of mice that were either feeding randomly or fasted for 14 hr, a state at which AgRP neurons are physiologically activated ( Figure 1H ). This analysis revealed an upregulation of BAT myostatin expression in fasted mice ( Figure 4D ). To further address whether AgRP neuron activation not only increases BAT myostatin expression but also circulating myostatin levels, we assessed myostatin concentrations in serum of control and hM3D Gq AgRP mice 1 hr following CNO application. Circulating myostatin concentrations increased by z20% in mice with activated AgRP neurons compared to controls ( Figure S4B ). In contrast, myostatin mRNA expression remained unaltered in hM3D Gq POMC mice ( Figure S4C) .
Interestingly, BAT-precursor cells originate from a Myf-5-positive lineage, which can give rise either to myocytes or brown adipocytes and b adrenergic stimulation can potently direct their gene expression profile and differentiation toward the brown adipocyte lineage (Kajimura et al., 2009; Seale et al., 2008; Timmons et al., 2007) . Thus, the profoundly and coordinately deregulated gene expression profile in BAT toward a myogenic signature together with the pre-described reduction in energy expenditure in mice upon chemogenetic AgRP neuron activation may point toward reduced sympathetic activation of BAT upon AgRP neuron activation (Krashes et al., 2011) . Thus, we directly recorded BAT sympathetic nerve activity (SNA) in control and hM3D Gq AgRP mice following intravenous injection of CNO. BAT SNA was rapidly suppressed following chemogenetic activation of AgRP neurons ( Figures 4E and 4F) . Next, we investigated whether the suppression of BAT SNA upon chemogenetic AgRP cell activation could contribute to the insulin resistance-inducing effect of activating these neurons. When we compared the blood glucose-lowering effect of insulin in CNO-treated control and hM3D Gq AgRP mice, which had been either injected with saline or a b3 agonist prior to the insulin tolerance test (ITT), pre-treatment with the b3 agonist abrogated the ability of AgRP neuron activation to impair systemic insulin sensitivity ( Figure 5A ). These experiments clearly indicate that AgRP neuron activation-dependent suppression of BAT SNA functionally contributes to the development of systemic insulin resistance upon AgRP neuron activation. Myostatin deficiency enhances BAT differentiation and function and protects from HFD-and high glucose-induced insulin resistance in myocytes (Braga et al., 2013; Kim et al., 2012; Zhang et al., 2011) , and myostatin acutely blunts insulin signaling in cultured myocytes and hepatocytes (Bonala et al., 2014) . To assess whether myostatin can also induce insulin resistance in brown adipocytes, we investigated the effect of incubating cultured immortalized brown adipocytes with increasing doses of myostatin on insulin-evoked AKT phosphorylation. This analysis revealed that pre-incubation with recombinant myostatin suppressed insulin's ability to promote AKT phosphorylation in parallel to its ability to activate SMAD2/3 phosphorylation (Figures 5B and 5C ).
Next, we compared the ability of AgRP neuron activation to impair insulin sensitivity during an ITT in hM3D Gq AgRP mice pretreated with a myostatin-blocking antibody (Ab) or an isotype control immunoglobulin (Smith et al., 2015) . IgG treatment had no effect on AgRP neuron-mediated insulin resistance upon CNO injection in hM3D Gq AgRP mice ( Figure 5D ). However, while injection of the myostatin Ab did not affect insulin tolerance in CNO-treated control mice, it attenuated the ability of CNOdependent AgRP neuron activation to impair systemic insulin sensitivity ( Figure 5D ). Thus, our experiments indicate that AgRP neuron-dependent activation of myostatin expression significantly contributes to the manifestation of systemic insulin resistance.
In Vivo Identification of Neurons Activated Downstream of AgRP Neuron Activation
To investigate the neurocircuitry underlying AgRP neuron activation-evoked impairment of systemic insulin sensitivity and myostatin expression in BAT, we employed 18 fluoro-deoxyglucose (FDG) positron emission tomography (PET) scanning in order to identify in vivo, which brain areas exhibit altered 18 FDG accumulation as a readout for neuronal activation in response to chemogenetic AgRP neuron activation. A significant activation pattern was observed in CNO-treated hM3D Gq AgRP mice in regions consistent with previously described projections of AgRP neurons, including the mediobasal hypothalamus, the LHA, the bed nucleus of the striae terminalis (BNST), raphe nuclei, nucleus accumbens, the parabrachial nucleus (PBN), the periaqueductal gray (PAG), the brainstem ( Figures S5A-S5F) , and in regions that are less well-appreciated as direct AgRP neuron projection sites such as the motor cortex and cingulate cortex, the somatosensory cortex, as well as the hippocampus (Figures S5G-S5L ). While the major advantage of PET-based activity mapping clearly stems from the fact that it allows to assess neuronal activation in vivo, PET scans have limited spatial resolution of 300 mm.
Thus, we complemented the PET-based analysis of neuronal networks activated in response to AgRP neuron activation through systematic assessment of cFos immunoreactivity. Induction of cFos expression was observed in the PVH, LHA, aBNST as well as the dorsal raphe nucleus in hM3D Gq AgRP (Figures S6A-S6E) . Thus, this analysis confirmed the activation pattern of neurons activated downstream of AgRP neurons as (D) qRT-PCR analysis of Myostatin (Mstn) in the BAT of mice fasted for 14 hr or random fed (n = 5 fasted versus 8 random fed). Mice were killed by decapitation and the BAT harvested 2-3 hr into the dark cycle. (E) BAT sympathetic nerve recordings at baseline, and time course changes of BAT SN activity after CNO administration from baseline of hM3D Gq AgRP and hM3D Gq WT mice (n = 7 versus 12). Data are represented as mean ± SEM. *p % 0.05, **p % 0.01, and ***p % 0.001 as determined by unpaired Student's t test (C, D and F) and, two-way ANOVA followed by Bonferroni post hoc test for BAT SNA recordings (E). See also Figure S4 and Tables S1 and S2. revealed by 18 FDG PET imaging in vivo. It should be pointed out that both techniques may also detect indirect changes in neuronal activity as a consequence of activating GABAergic AgRP neurons, such as via inhibition of local inhibitory interneurons.
Distinct AgRP Projections Mediate the Feeding versus Glucose Regulatory Action of AgRP Neurons
To investigate which AgRP projections mediate the acute glucose regulatory action of these neurons, we employed an op- Food intake before (pre), during (stim), and after (post) photostimulation (1 hr per period) and insulin tolerance test (ITT) and respective area under the curve (AUC) in ChR2
AgRP mice and ChR2 WT mice laser-light stimulated in the following AgRP neuron projection sites: (A and B) the paraventricular nucleus of the hypothalamus (PVH) (n = 7 versus 6); (C and D) the lateral hypothalamic area (LHA) (n = 14 versus 11-13); (E and F) the ventro-lateral anterior bed nucleus of the stria terminalis (aBNST_ vl ) (n = 10 versus 9); (G and H) the dorsomedial part of the anterior bed nucleus of the stria terminalis (aBNST_ dm ) (n = 11 versus 9); (I and J) the dorsal raphe nucleus (DR) (n = 8-9 versus 6); and (K and L) the dorsal vagal complex (DVC) (n = 6-7 versus 5-6). Data are represented as mean ± SEM. *p % 0.05, **p % 0.01, and ***p % 0.001 as determined by one-way ANOVA followed by Newman-Keuls post hoc test for food intake, by two-way ANOVA followed by Bonferroni post hoc test for ITT curves and by unpaired Student's t test for the AUC graphs.
togenetic mapping approach in ChR2 AgRP mice. To this end, we implanted optical fibers into AgRP neuron projection sites (Figures S7) and compared the effect of stimulating AgRP fibers specifically in these projection sites on food intake and insulin sensitivity as assessed by ITT. Stimulating AgRP / PVH projections revealed light-evoked activation of feeding as previously described (Atasoy et al., 2012; Betley et al., 2013 ) but failed to impair systemic insulin sensitivity ( Figures 6A and 6B ). In contrast, activation of AgRP / LHA projections increased feeding but also induced peripheral insulin resistance ( Figures 6C  and 6D ). Interestingly, whereas stimulation of AgRP / aBNST projections in the ventrolateral part of the aBNST (aBNST_ vl ) in ChR2 AgRP mice did not modulate feeding, it clearly impaired systemic insulin sensitivity ( Figures 6E  and 6F ). When we targeted a more dorsomedial part (aBNST_ dm ), photostimulation evoked a 4-fold increase in feeding in comparison to stimulating the same site in control animals but had no effect on insulin sensitivity ( Figures 6G and 6H) . Thus, our experiments reveal a functional dichotomy of AgRP / aBNST projections in control of food intake and those in control of peripheral insulin sensitivity. On the other hand, stimulating AgRP / dorsal raphe projections (DR), and AgRP / dorsal vagal complex (DVC) projections had no effect on feeding or on systemic insulin sensitivity ( Figures 6I-6L Figures 7B-7D ). Moreover, activation of AgRP / PVH, AgRP / DR, and AgRP / DVC projections failed to induce myostatin mRNA expression in BAT, consistent with the failure of these projection stimulations to affect systemic insulin sensitivity ( Figures 7A, 7E , and 7F).
DISCUSSION
Tight regulation of blood glucose concentrations is essential for the survival of the organism. Accordingly, the brain not only controls food intake and energy expenditure, but also coordinately adapts nutrient fluxes across different organs in conjunction with external energy supply (Vogt and Brü ning, 2013) . Although our detailed understanding about food intake regulatory neurocircuits has rapidly evolved over the last years (Gautron et al., 2015; Betley et al., 2013; Carter et al., 2013; Wu et al., 2012) , how the CNS controls peripheral glucose metabolism is less well defined. Recent experiments largely derived from animals with chronically altered leptin and/or insulin signaling in the ARH, and particularly AgRP and POMC neurons, have substantiated a function for these neurons in controlling HGP and peripheral insulin sensitivity in the long term (Hill et al., 2010; Kö nner et al., 2007) . Our experiments demonstrate that both chemogenetic and optogenetic activation of AgRP neurons can acutely induce peripheral insulin resistance. While chemogenetic activation of AgRP neurons impairs both glucose tolerance and insulin sensitivity, optogenetic activation only impairs insulin sensitivity. This may stem from a quantitative difference depending on how many AgRP neurons are activated in either experimental approach, as our transgenic chemogenetic approach activates more AgRP neurons compared to unilateral laser stimulation in the ARH of AgRP neuron projection sites: (A) the paraventricular nucleus of the hypothalamus (PVH) (n = 4-6); (B) the lateral hypothalamic area (LHA) (n = 13-9); (C) the ventro-lateral part of the anterior bed nucleus of the stria terminalis (aBNST_ vl ) (n = 10 versus 7); (D) the dorso-medial of the anterior bed nucleus of the stria terminalis (aBNST_ dm ) (n = 10 versus 9); (E) the dorsal raphe nucleus (DR) (n = 7-6); and (F) the dorsal vagal complex (DVC) (n = 3-6). Data are represented as mean ± SEM. *p % 0.05 as determined by unpaired Student's t test.
ChR2
AgRP mice. Alternatively, differences in the genetic background (C57bl6 for hMD3 Gq AgRP mice and C57bl6/129s for ChR2 AgRP mice as well as their respective controls) may also account for the phenotypical difference between the chemo-and optogenetic model with respect to glucose tolerance despite them showing the same phenotype for food intake, ITT, and BAT gene expression. Nevertheless, the fact that unilateral AgRP neuron stimulation alone is sufficient to promote systemic insulin resistance points to the dominant nature of this pathway in controlling glucose homeostasis. Thus, we reveal an important regulatory principle in the physiological control of fuel fluxes, since AgRP neurons are the most effective hunger-communicating cells and therefore provide an ideal effector to impair peripheral glucose deposition in the short term, at times when external energy sources are limited. The fact that no acute glucose regulatory effect is observed during the same time course following POMC neuron activation indicates that this short-term glucose regulatory effect governed by AgRP neurons may be AgRP-and MC4R-independent. Similarly, the acute orexigenic effects of AgRP neuron activation is mainly melanocortin-independent as acute optogenetic stimulation of AgRP neurons in Ay mice does not impair light-evoked feeding (Aponte et al., 2011) . AgRP neurons co-express NPY as well as the inhibitory neurotransmitter GABA, both of which specifically contribute to the short-term feeding regulatory function of AgRP neurons (Krashes et al., 2013) . Thus, further studies will have to clearly establish which neuropeptides or neurotransmitters mediate the acute glucose regulatory function of AgRP neurons.
In addition to the possibility that AgRP neuron-dependent acute regulation of systemic insulin sensitivity is independent of melanocortin signaling, the difference between CNO-induced activation of AgRP and POMC neurons may also stem from a fundamental difference in the architecture of AgRP and POMC neuron circuits. Recent studies from Atasoy et al. (2014) revealed a different innervation pattern of AgRP and POMC neuron projections in the PVH. AgRP projections densely target the soma of PVH neurons, while POMC projections primarily innervate the dendrites of these PVH neurons, indicating that while AgRP neurons potently control firing of downstream targets, POMC neurons may provide a more modulatory effect on the same targets. Whether this differential output organization also holds true for the glucose regulatory AgRP projection sites identified in the current study will have to be investigated in upcoming experiments.
Interestingly, while most of the models with chronically altered leptin and insulin signaling in AgRP neurons manifested with an impairment of insulin's ability to suppress HGP, insulin still fully suppressed HGP in the short term in our present model of acute AgRP neuron activation. Thus, overt de-regulation of HGP by altered AgRP neuron activity requires additional long-term, likely MC4R-mediated signals, as suggested from our experiments or by re-constituting MC4R expression in the brainstem (Berglund et al., 2014) .
On the other hand, the acute and profound effect of AgRPdependent impairment of systemic insulin sensitivity results from inhibition of insulin-stimulated glucose uptake into BAT. Again, the absence of altered BAT glucose uptake in POMC-activated mice suggests a MC4R-independent mechanism for this acute effect, in addition to the documented chronic effect of MC4R re-expression in the LHA on BAT glucose uptake (Morgan et al., 2015) .
Another key finding of the present study is how rapidly, within only 1 hr of AgRP neuron activation, the transcriptional signature of BAT is altered toward a coordinated upregulation of mRNAs, which are characterized as myocyte-specific genes. These findings indicate that even in BAT of adult mice, a characteristic skeletal muscle transcriptional program can be established within short time of activating AgRP neurons. Among the muscle-specific transcripts upregulated in response to AgRP neuron activation, myostatin stood out, both by the degree of upregulation upon activation of AgRP neurons and by its previously documented role in BAT differentiation and function. Importantly, myostatin expression is upregulated in obesity and myostatin-deficient mice exhibit increased muscle mass, decreased adiposity, and increased insulin sensitivity (McPherron and Lee, 2002) . While the effect of myostatin deficiency may largely depend on increased muscle mass, there is evidence for a muscle-independent function of myostatin in controlling BAT differentiation and function. For example, overexpression of myostatin impairs BAT differentiation in vitro and predadipocytes from myostatin-deficient mice exhibit an increased propensity to differentiate into brown adipocytes (Braga et al., 2013) . Moreover, blockade of the myostatin receptor activin receptor IIb activates functional brown adipogenesis and thermogenesis (Fournier et al., 2012) . Of note, in the gene expression analysis presented here, thermogenic genes were not dysregulated despite a clear reduction in sympathetic nerve activity following AgRP neuron activation. One explanation for this could be that these genes may follow a different time course of regulation.
Finally, we demonstrate that in cultured brown adipocytes myostatin can inhibit insulin-induced AKT activation. More importantly, our in vivo experiments reveal that acute pharmacological blockade of myostatin attenuates the ability of activated AgRP neurons to cause insulin resistance. Clearly, our experiments define myostatin as an attractive target for obesity-associated insulin resistance, as it may develop in part as a consequence of altered AgRP neuron function.
In addition to the identification of mechanisms responsible for AgRP neuron-dependent instatement of insulin resistance in peripheral tissues, our experiments define key projection sites within the CNS, which mediate AgRP neuron-dependent insulin resistance as the aBNST vl and the LHA. While previous studies have already linked the activity of neurons in the LHA to the control of BAT function through control of sympathetic innervation of this tissue (Morgan et al., 2015) , to our knowledge, no data exist so far regarding a role for the aBNST in control of BAT function. Interestingly, using elegant approaches based on rabies virus tracing, Betley et al. (2013) identified the aBNST and PVH as the AgRP neuron projection sites innervated by the largest number of AgRP neurons, with 18.3% of AgRP neurons projecting to the BNST. Regarding the aBNST neurons responsible for mediating the ability of activated AgRP neurons to cause insulin resistance, we identified them as being located predominantly in the aBNST vl . With respect to the efferent structures targeted by the aBNST, studies have already revealed a plethora of efferences arising from this nucleus and innervating both structures related to control of autonomic responses as well as ingestive behavior (Dong and Swanson, 2006) . Thus, our study clearly indicates a functional compartmentalization between these parts of the aBNST in terms of regulating food intake and those controlling autonomic responses. Clearly, further studies are needed to reveal the exact molecular identity of aBNST neurons in control of BAT function as well as the downstream circuitries targeted by these cells. Similarly, experiments investigating the nature of synaptic connections from AgRP neurons onto BNST neurons will be required to address whether the effects reported here are mediated by direct monosynaptic contacts or stimulation of AgRP-fibers traveling in very close proximity to the regions probed.
Finally, although we have not investigated other potential AgRP neuron projections sites in control of systemic insulin sensitivity to the full extent, the difference in the complexity of neurocircuits involved in control of feeding behavior compared to the relatively simple architecture of those in control of peripheral insulin sensitivity is obvious. This is reasonable in light of the complex behaviors that have to be integrated in the control of feeding, including assessing the nature of the food-containing environment, assigning a rewarding value to food, and finally, not only adapting autonomic responses to substrate availability but also to coordinate locomotor activity and foraging behavior.
Taken together, our experiments reveal the basic architecture for short-term control of peripheral insulin sensitivity governed by the key nutrient communicating AgRP neurons. Further defining the targets of the AgRP / LHA and AgRP / aBNST vl circuits as well as their effectors in BAT, such as myostatin, in control of peripheral insulin sensitivity thus may allow to define novel targets for the improvement of glucose homeostasis in subjects suffering from obesity and obesity-associated insulin resistance.
EXPERIMENTAL PROCEDURES Animal Care
All animal procedures were conducted in compliance with protocols approved by local government authorities (Bezirksregierung Kö ln) and were in accordance with NIH guidelines. Mice were housed at 22 C-24 C using a 12-hr light/12-hr dark cycle. Animals had ad libitum access to water at all times, and food was only withdrawn if required for an experiment. All experiments have been performed in adult mice.
Genetic Mouse Models
Generation of ROSA26CAGSloxSTOPloxhMD3 Gq mice is described in the Supplemental Experimental Procedures. All other mice used in this study have been previously described: AgRP-IRES-Cre (AgRP Cre ) (Tong et al., 2008) , POMC-Cre (Balthasar et al., 2004) , tdTomato reporter (B6;129S6-Gt(ROSA)26Sor tm9(CAG-tdTomato)Hze /J (Madisen et al., 2010) , and B6;129S-Gt(ROSA)26Sor tm32(CAG-COP4 * ChR2(H134R)EYFP) Ai32; (Madisen et al., 2012) .
CNO Administration
Clozapine-N-oxide (CNO; Sigma) was injected intraperitoneally (i.p.) at a dose of 0.3 mg/kg BW unless stated differently.
Photostimulation and Calcium Imaging Photometry
Photostimulation and calcium imaging photometry were performed as previously described (Betley et al., 2013; Chen et al., 2015) . For detailed experimental procedures, see the Supplemental Experimental Procedures.
Anti-myostatin Blockade and b3-Adrenergic Stimulation
Twelve hours prior to the ITT, subcutaneous (s.c.) injections of 5 mg/kg BW control IgG or anti-myostatin antibody (LSN2478185) were performed as previously described (Smith et al., 2015) . The selective b3-adrenergic sympathomimetic drug CL 316,243 hydrate (1 mg/kg BW) or vehicle (saline) was co-administered together with CNO 20 min prior to the ITT.
Sympathetic Nerve Activity Recording Sympathetic nerve activity (SNA) subserving brown adipose tissue (BAT) was recorded as previously described (Tovar et al., 2013) . 
Positron Emission Tomography Scans
Statistical Analyses
All values are expressed as the mean ± SEM. Statistical analyses were conducted using GraphPad PRISM (version 5.0a). Data recorded from an animal subjected to two different treatments (CNO versus vehicle) were analyzed for statistical significance using a paired two-tailed Student's t test. Datasets with only two independent groups were analyzed for statistical significance using an unpaired two-tailed Student's t test, unless indicated otherwise in the figure legends. Datasets with more than two groups were analyzed using one-way ANOVA followed by Newman-Keuls post hoc test. Datasets subjected to two independent factors were analyzed using two-way ANOVA followed by Bonferroni post hoc test. All p values %0.05 were considered significant (*p % 0.05, **p % 0.01 and ***p % 0.001).
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO: GSE77766. Please refer to http://www.ncbi.nlm.nih.gov/geo/info/linking.html.
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Supplemental Information includes Supplemental Experimental Procedures, seven figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2016.02.044.
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